The global peptide drug conjugates market is anticipated to grow at a CAGR of 9.4% during the forecast period (2023-2030). A significant the market growth is anticipated to come from the extensive clinical trial pipeline for peptide drug conjugates, coupled with increased research and development expenditures for PDC development and the rising burden of disease globally. For instance, in July 2021, Takeda Pharmaceutical Co., Ltd., collaborated with PeptideDream, to invest $3.5 billion to develop peptide drugs for neuromuscular disease. Furthermore, pharmaceutical companies are developing PDCs as focused therapeutic treatments for diseases such as cancer, viral infections, and metabolic disorders. Further, the increasing agreement and acquisition for Peptide Drug Conjugates is projected to drive market growth by promoting increased acceptance and usage of these devices.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/peptide-drug-conjugates-market
- In November 2022, Exelixis, Inc., and Cybrexa Therapeutics Inc., entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12 (alphalex™ exatecan), a clinical-stage, first-in-class peptide-drug conjugate (PDC) that utilizes Cybrexa’s proprietary alphalex technology to enhance delivery of exatecan to tumor cells.
- In June 2019, Peptidream Inc., a public Kanagawa-based biopharmaceutical company entered into a new Peptide Drug Conjugate collaboration agreement with Swiss-based Novartis AG. Under the agreement, PeptiDream used its proprietary Peptide Discovery Platform System (PDPS) technology for the identification of novel macrocyclic peptides for use as PDCs against multiple targets of interest selected by Novartis. Under the terms of the agreement, PeptiDream received an undisclosed upfront payment, R&D funding payments, and eligible to receive additional pre-clinical, clinical, approval, and commercial sales milestones.
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
- Segment Covered-
o By Type
o By Product
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- includes Angiochem Inc., Bicycle Therapeutics, Inc., Cybrexa Therapeutics Inc., Oncopeptides AB, and Novartis AG, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Peptide Drug Conjugates Market Report Segment
By Type
- Diagnostic
- Therapeutic
By Product
- Melflufen
- Lutetium
- ANG1005
- BT1718
- CBX-12
A full report of Peptide Drug Conjugates Market available @ https://www.omrglobal.com/industry-reports/peptide-drug-conjugates-market
Company Profiles
- AstraZeneca co.
- Camurus AB
- Chiasma, Inc.
- CRINETICS PHARMACEUTICALS
- Dauntless Pharmaceuticals
- Ipsen Biopharmaceuticals, Inc.
- Midatech Pharma PLC
- PeptiDream Inc.
- Peptron, Inc.
- Pfizer Inc.,
- Soricimed Biopharma
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
